Announcements

Job offersmore »

Tweeting Growers

Top 5 - yesterday

Top 5 - last week

Top 5 - last month

Exchange ratesmore »




CAN (ON): Aphria inks wholesale supply deal with Scientus Pharma

Aphria, through its subsidiary Pure Natures Wellness, entered into a major wholesale supply agreement with HydRx Farms. Under the terms of the Agreement, Aphria is committing to supply over 25,000 fully grown medical cannabis plants over the next 12 months to Scientus Pharma. The first delivery, under the agreement will occur in the middle of Aphria’s second quarter of 2018. Aphria expects to generate over $1.2 million of revenue from the wholesale supply agreement in each full quarter of
shipments, with gross margins consistent with previously executed wholesale agreements.



Scientus Pharma, a vertically-integrated biopharmaceutical company, is raising the bar of cannabinoid products from medical-grade to pharmaceutical-grade. Leveraging its proprietary, patent-pending formulation and processing technologies, Scientus Pharma is committed to leading the medical cannabis market towards pharmaceutical standards in manufacturing, formulations and dosing.

“Scientus Pharma shares our vision for providing high-quality products to medical cannabis patients, which is enabled by our 509-step Seed-to Sale quality assurance program,” said Vic Neufeld, Chief Executive Officer of Aphria. “Through this agreement, Scientus Pharma will get access to clean and safe cannabis, which is necessary in the biopharmaceutical cannabis industry. In return, Aphria will benefit from guaranteed product distribution advancing Aphria’s growth strategy.”

“Scientus Pharm intends to leverage this key raw material supply contract to help it lead the evolution of cannabinoid products from medical-grade to pharmaceutical-grade,” said Trevor Folk, Chief Executive Officer of Scientus Pharma. “Our proprietary extraction technology platform has solved the resin consistency issue that has here-to-for prevented that scientific advancement, and it is the foundation for Scientus Pharma’s pipeline of novel products.”

For more information:
Aphria Inc.
Vic Neufeld
President & CEO
1-844-427-4742
aphria.com

Scientus Pharma
209 Dundas St. E
PO Box 31 Whitby
Whitby, ON L1N 5R7
T: +1 844 493.7922
info@scientuspharma.com
scientuspharma.com

Publication date: 7/6/2017

 


 

Other news in this sector:

9/19/2017 US (NV): First plants are in at Marapharm's Las Vegas facility
9/19/2017 US (MD): University of Maryland cancels MMJ training
9/18/2017 Solution on the horizon for marijuana business banking issues
9/18/2017 "26 percent of Canadians consume cannabis"
9/15/2017 US: Nanoparticle cannabinoid drones to target lung cancer
9/13/2017 US (MI): Medical marijuana shops get temporary reprieve
9/13/2017 Canada: Supreme completes first sales with Aurora Cannabis
9/13/2017 CAN (ON): Tweed Farms to expand three-fold , acquires Garden City Growers
9/13/2017 US: Texas issues first medical marijuana license
9/12/2017 Cannabis Science participates in U.S.-Africa Policy Forum
9/11/2017 US (MA): AmeriCann secures $10,000,000 equity financing commitment
9/11/2017 US: Medical marijuana plants have started to grow in Maryland
9/8/2017 Planning for cannabis odor control in the design phase
9/8/2017 Indoor sunlight now available for medical cannabis growers
9/8/2017 Canada: Ontario to announce MMJ legalization plans today
9/6/2017 Cronos announces MMJ supply agreement in Germany
9/5/2017 US (CA): Future Farm makes progress on Riverside County cultivation facility
9/5/2017 CAN (QC): MYM receives permit approval to begin construction in Laval
9/5/2017 US (CA): "80% of MMJ at conference tested positive for contaminants"
9/5/2017 Israeli company to set up 4 US cannabis factories